Protecting against brain damage by improving treatment in neonates with hypoglycemia.

• Conditions: E16.2; Hypoglycaemia, unspecified

• Registration Number: DRKS00024086
• Lead Sponsor: Heinrich-Heine Universität

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-15
• Results First Posted: 2024-03-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 957

Inclusion Criteria

Newborns with and without hypoglycemia born at the University Hospital Düsseldorf between March 2018 - June 2022 or 2010 - 2015

Exclusion Criteria

Lack of parental consent. Prematurity <35+0 weeks gestation.

Excluded for analysis of the primary endpoint are all children in whom another nonhyperglycemic cause of developmental disability is/will be known.

Patients receiving glycemic therapy (e.g., infusion/gastric tube during CPAP or similar) due to another clinical indication (not hypoglycemia) will remain in the study and may only be excluded from certain endpoints in the analysis.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eurological outcome in Bayley Scales of Infant Development (BSID-II) at 2 years of age and in Wechsler Intelligence Scale for Children (WISC-V) at 7-11 years of age.